We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sound Pharmaceuticals

News List

Sound Pharma Advances Pivotal Phase 3 Clinical Trials in Meniere's Disease americanpharmaceuticalreview
June 17, 2020
Sound Pharmaceuticals announced the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere's Disease (STOPMD-3).
University of Oxford, Sound Pharmaceuticals Complete Phase 2 Bipolar Disorder Study americanpharmaceuticalreview
May 11, 2020
The University of Oxford and Sound Pharmaceuticals (SPI) announced the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD).
Sound Pharmaceuticals Announces Positive Topline Results from SPI-1005 Phase 2b Trial americanpharmaceuticalreview
June 26, 2019
Sound Pharmaceuticals announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center Phase 2b study in Meniere's Disease (MD).